Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Clinic Secret vs Hims & Hers

By GLP-1 ScorecardUpdated

Clinic Secret
Site position #343

Lower grade

Hims & Hers
Site position #56

Higher grade

Score comparison

Hims & Hers has the higher recorded score — 75.6/100 to 61.1/100.

Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueHims & Hers +27
55
82
Dose & formulationHims & Hers +14
64
78
Clinical oversightClinic Secret +19
74
55
Labs & monitoringHims & Hers +28
52
80
FulfillmentHims & Hers +25
59
84
Contract termsHims & Hers +19
61
80
Clinic Secret · top barHims & Hers · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricClinic SecretHims & Hers
WeighScore61.1/10075.6/100
GradeCC
Site position#343#56
Semaglutide$196/mo (starting dose, compounded)$199/mo
Tirzepatide$196/mo (compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Clinic Secret

Site position #343 · C

Strengths

  • Low entry price starting at $49/week with no membership fees
  • Monthly price does not increase as dosage rises
  • Fast nationwide shipping in about three days
  • Asynchronous intake available in some states (no required video call)
  • Money-back guarantee tied to weight-loss goals

What to consider

  • Newly launched (late 2025); limited independent track record
  • Compounded medications only; no FDA-approved brand options
  • Named compounding pharmacy not disclosed
  • State availability not published
  • No insurance accepted
Hims & Hers

Site position #56 · C

FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.

Strengths

  • Nationwide
  • Polished app
  • Strong brand trust

What to consider

  • Tirzepatide pricing inconsistently disclosed
  • Industry-wide compounding scrutiny

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard